Coronavirus Ask the Expert Webinars

View next
Published on January 12, 2021
Upcoming Webinars
There are currently no upcoming Answers Now events scheduled. We encourage you to take a look at the replays and transcripts below. Please check back shortly as this page is updated regularly.
Past Webinars
New Clinical Trials for MPNs in 2021 and Beyond
There used to be a stigma surrounding participation in clinical trials. Moving into 2021, patients have a more nuanced understanding but questions remain: How will I be monitored? How will my care team change? How does Covid fit into all this?
Watch our discussion between our host Ruth Fein, Dr. Gabriela Hobbs, active clinical researcher and leader of the MPN research program at Massachusetts General Hospital, and Dr. Angela Fleishman, Assistant Professor of Medicine at the Institute for Immunology at the University of California, Irvine. They discussed clinical trials in the age of combination therapies, finding a clinical trial that may be right for you and more.
This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for program content.
Reflection On Living With CLL in 2020 & Hopes for the New Year
2020 has been a difficult year. For those of us living with chronic lymphocytic leukemia (CLL), there have been moments of deep anxiety, hurdles in our treatment plans, and difficulties knowing what to do next. 2021 will bring new challenges, hopes, and questions. Should we be first in line to receive a COVID-19 vaccination? How should we proceed as the world looks to reopen?
Watch as Patient Power Co-Founder & CLL Survivor Andrew Schorr and Patient Advocate Michele Nadeem Baker, are joined by Dr. Nicole Lamanna, Hematologist at Columbia University Herbert Irving Comprehensive Cancer Center and Dr. Jennifer Brown, Professor of Medicine at Harvard Medical School, in a reflection on living with CLL in 2020, and a discussion of what the new year may bring.
This program is sponsored by AbbVie, Inc. and Genentech, Inc. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
How Do Racial and Socioeconomic Disparities Affect MPN Patients?
Watch our discussion between our host, Ruth Fein, patient-advocate Taja Shabazz-Simmons and Dr. Irum Khan, Assistant Professor of Hematology/Oncology in the Department of Medicine at the University of Illinois College of Medicine.
Dr. Khan is passionate about caring for traditionally underserved patients every day and her research focuses on racial and socioeconomic disparities in treatment patterns and outcomes. Who is predisposed to scarring, bleeding, clotting? Where do institutions tend to fall short and how can they better to overcome barriers? How do disparities in access to care affect outcomes? And what can we, as an MPN community, do to advocate for all MPN patients to get the best care possible?
This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for program content.
ASH 2020 CLL Daily Wrap-Up
Watch our live recap of the latest chronic lymphocytic leukemia (CLL) news from the 62nd American Society of Hematology (ASH) Annual Meeting. ASH is the world’s most comprehensive hematology event of the year where experts review thousands of scientific abstracts, highlighting updates on the most critical topics in hematology. Some of the field’s top doctors shared their thoughts on emerging research, clinical trials, and how current events such as COVID-19 are impacting cancer patients.
This program is sponsored by Pharmacyclics. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
ASH 2020 MPN Ask Me Anything
Watch our live Q&A with MPN expert Dr. Ruben Mesa! Dr. Ruben Mesa is the director of UT Health San Antonio MD Anderson Cancer Center. In Dr. Mesa's more than 20 years researching MPNs, he's built an international reputation as an expert on the subject. He was joined by Patient Power co-founder and patient advocate Esther Schorr. Dr. Mesa and Esther also discussed the latest MPN news from the world’s most comprehensive hematology event of the year, the 62nd American Society of Hematology (ASH) Annual Meeting.
This program is sponsored by BMS-Celgene. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
ASH 2020 MPN Daily Wrap-Up
Watch a live recap of the latest myeloproliferative neoplasm (MPN) news from the 62nd American Society of Hematology (ASH) Annual Meeting. ASH is the world’s most comprehensive hematology event of the year, where experts review thousands of scientific abstracts, highlighting updates on the most critical topics in hematology. Many of the field’s top doctors shared their thoughts on emerging research, clinical trials and how current events such as COVID-19 are impacting cancer patients.
This program is sponsored by BMS-Celgene. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
ASH 2020 CLL Ask Me Anything
Watch a live Q&A with chronic lymphocytic leukemia (CLL) expert Dr. Philip Thompson! Dr. Thompson is part of the world's largest leukemia department at The University of Texas MD Anderson Cancer Center in Houston, Texas. He was joined by Patient Power co-founder and patient advocate Esther Schorr. Dr. Thompson and Esther also discussed the latest CLL news from the world’s most comprehensive hematology event of the year, the 62nd American Society of Hematology (ASH) Annual Meeting.
This program is sponsored by Pharmacyclics. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Live ASH 2020 Myeloma Answers Now
Watch our live Q&A with multiple myeloma expert Dr. Joshua Richter! Dr. Richter is Assistant Professor of Medicine at the Tisch Cancer Institute at Mount Sinai School of Medicine. He has extensive clinical trial experience and has been published in the New England Journal of Medicine, Blood and the Journal of Clinical Oncology. He was joined by Patient Power co-founder and patient advocate Esther Schorr. Dr. Richter and Esther also discussed the latest multiple myeloma news from the world’s most comprehensive hematology event of the year, the 62nd American Society of Hematology (ASH) Annual Meeting.
This program is sponsored by GlaxoSmithKline. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
ASH 2020 Myeloma Daily Wrap-Up
Watch a live recap of the latest MM (multiple myeloma) news from the 62nd ASH Annual Meeting. ASH is the world’s most comprehensive hematology event of the year where experts review thousands of scientific abstracts, highlighting updates on the most critical topics in hematology. Some of the field’s top doctors shared their thoughts on emerging research, clinical trials, and how current events such as COVID-19 are impacting cancer patients. Hear exciting MM news from ASH 2020!
This program is sponsored by GlaxoSmithKline. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Weighing Decisions & Outcomes for MPN Stem Cell Transplants
Weighing all of the variables that are involved in considering a stem cell transplant – pros and cons of treatment, affordability, success rate – can feel suffocating. And that’s before the procedure itself! In this special installation of our MPN Answers Now series, our host Andrew Schorr SPOKE with patient advocate, Rabbi Ronald Roth and Dr. H. Joachim Deeg of the Seattle Cancer Care Alliance about transplant decision-making and outcomes.
What does this decision-making process entail? What should a transplant candidate do before and after the procedure? Is there research on the horizon that will change the calculus for patients in the coming years?
This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for program content.
Experts Answer Critical Questions on CLL Testing
Navigating the landscape of CLL testing can be overwhelming. What does your blood test result mean? Measurable Residual Disease (MRD) testing allows people to stop therapy, but how does that impact you? What trends can my test results reveal about my overall health?
Experts answered important questions about radiation, CT scans, MRI, bloodwork, and biopsy. Patient Power Co-Founder and CLL Survivor Andrew Schorr was joined by Dr. Susan LeCLair, (retd.) Chancellor professor, Department of Medical Laboratory Science at University of Massachusetts, and Dr. Adam Kittai, Hematologist at OSU Comprehensive Cancer Center, for this expert panel.
This program is sponsored by AbbVie, Inc. and Genentech, Inc. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Choosing A CLL Treatment to Match Your Lifestyle and Needs
Whether you have been newly diagnosed with CLL or are returning for further treatment, it can be overwhelming to research and choose a CLL treatment pathway. With factors such as cost, side effects, usage, and now with multiple treatment options to choose from, how do you choose the right and most effective treatment to continue living your life the way you want?
Patient Power Co-Founder and CLL Survivor Andrew Schorr was joined by Dr. Jeff Sharman, Director of Research at Willamette Valley Cancer Institute, and Dr. Catherine Callaghan Coombs, Assistant Professor at UNC School of Medicine as they discussed the different CLL treatment options and how to create the best treatment pathway to achieve your health and life goals.
This program is sponsored by AbbVie, Inc. and Genentech, Inc. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
New Targeted Therapies for RET Gene in Lung Cancer
The majority of lung cancer patients have non-small cell lung cancer (NSCLC), and a small percentage of those patients have the RET gene, also called RET fusion-positive lung cancer. What is the RET gene mutation, and how is it treated? We have information that is hot off the research presses on the newest targeted therapies.
During this lung cancer Answers Now program, our host talked to Dr. Viola Zhu from University of California at Irvine and Dr. Karen Reckamp, Director of Medical Oncology at Cedars-Sinai Cancer about the RET gene and new treatment options for patients with metastatic RET fusion-positive NSCLC.
This program is sponsored by Blueprint Medicines. This organization has no editorial control. It is produced by Patient Power, and Patient Power is solely responsible for program content.
What Women with MPNs Need to Know
Does sex affect the way that people present MPNs? In some ways, yes. Women are more likely to have ET than PV or MF. And while the standard course of treatment can be identical for men and women, there are specific considerations for women.
Listen to a discussion about the cutting-edge research into sex and MPNs and how women can manage their care team in a way that supports their reproductive health whether they're 25 or 65. Our host Ruth Fein talked to Dr. Ellen Ritchie, Assistant Professor of Medicine and a member of the Leukemia Program at the Weill Cornell Medical College of Cornell University and the New York Presbyterian Hospital in New York City.
This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for program content.
How to Manage Prostate Cancer Side Effects and Reduce Suffering
Talking honestly about one’s medical realities in the doctor’s office takes practice, but it is a crucial step to take. Watch as experts discussed how transparent doctor-patient relationships can improve prostate cancer outcomes.
In the final segment of our prostate cancer Answers Now series, our patient host spoke with Dr. Atish Choudhury, Co-Director of the Prostate Cancer Center at Dana-Farber Cancer Center about the importance of open communication between patients and physicians. What are the best treatment options? What side effects may I experience? What will my quality of life be? Expect all of these answers and more.
This program is sponsored by Bayer. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Sinus and Respiratory Infections for CLL Patients During COVID
Cold and flu season is approaching, and for those with chronic lymphocytic leukemia (CLL), the increased risk of sinus and upper respiratory infections during this time can rightly warrant extra precaution. This year, that is paired with entering flu season during a worldwide pandemic. Listen in as a team of experts shared important tips for staying safe and healthy in the months to come.
Patient Power Co-Founder and CLL Survivor Andrew Schorr will be joined by Co-Host and Patient Advocate Michele Nadeem-Baker as they interview Dr. Stacey Gray, Director, Sinus Center at Massachusetts Eye and Ear, on how to navigate cold and flu season as a CLL patient.
This program is sponsored by AbbVie, Inc. and Genentech, Inc. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Can Telemedicine Improve the Quality of Your MPN Care?
The Coronavirus pandemic forced an explosion in telemedicine where many people see their MPN doctor on a screen rather than in an exam room. Is it just as good? Without your doctor touching you are they really able to provide quality care?
What does this mean for how MPN patients will receive clinical care moving forward? What will the trade-offs be, if any?
We will cover these topics to help viewers navigate the virtual world of healthcare, and ideally maintain the quality of their doctor-patient relationships. Our host talked to Dr. Aaron Gerds, Deputy Director for Clinical Research at Taussig Cancer Institute, Associate Professor of Medicine, physician and MPN expert, about the role telemedicine and technology will play in MPN treatment moving forward.
This program is sponsored by Incyte and is produced in partnership with the MPNRF. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
PSA and Imaging for Prostate Cancer Patients
This program is sponsored by Bayer. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
MPNs in Children, Teenagers, and Young Adults
While most myeloproliferative neoplasm (MPN) patients are older adults, children and young adults can be affected as well, and research & treatment for pediatric MPNs is a growing field. Find out what we know and hope to discover about MPNs in children with our host Ruth Fein, patient advocate Portia Pliam, and special guest Dr Nicole Kucine, who specializes in pediatric MPNs as Assistant Professor of Pediatrics at Weill Cornell Medicine.
How do you diagnose MPNs in children and young adults? What treatment options are available? Do they differ from treatments for adults with MPNs? What are the unique challenges of this rare pediatric condition? And finally, what does the future look like for children with MPNs?
This program is sponsored by Incyte and is produced in partnership with the MPNRF. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Everything You've Always Wanted to Know About HER2
HER2 has been a major part of the breast cancer vocabulary since the 1980s. Nowadays everyone knows their status as a matter of course. But what exactly does that mean?
Dr. Sara Hurvitz, Director, Breast Cancer Clinical Trial Program at UCLA Medical Center, and patient advocate and writer Andrea Hutton talked about HER2 in depth. Whether you’re positive or negative, this discussion helped clarify what we know about human epidermal growth factor receptor 2 and how emerging research is changing our understanding of these proteins and, in turn, the treatment options for breast cancer patients of all stripes.
This program is supported by an educational grant from Daiichi Sankyo. This organization has no editorial control. It is produced by Patient Power and Patient Power is solely responsible for program content.
Immunotherapy For Lung Cancer Brings Treatment Breakthroughs
Immunotherapies have radically changed treatment for non-small cell lung cancer (NSCLC) patients. In fact, the PD-L1/PD-1 blockade is a bona fide breakthrough. What does this fast-moving course of research and treatment mean for lung cancer patients of all persuasions?
Watch as host and patient advocate Lisa Goldman talked to Dr. David Carbone of the Ohio State University about existing PD-L1/PD-1 treatment options and those currently in development.
Prostate Cancer and Making Sense of nmCRPC Treatment Options
In 2018, patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) were watching and waiting. Two years later there are three novel androgen receptor inhibitors available. But more options mean more questions for doctors and for patients. In this first installment of our prostate cancer Answers Now series, we explored these emerging questions around who should use what when, and why. We gave an overview of the disease and current treatment options. Our Patient Power host will talk to Dr. Eleni Efstathiou from MD Anderson Cancer Center in Texas and Dr. Tom Beer, Chair of Prostate Cancer Research at OSHU.
This program is sponsored by Bayer. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
The Road to Curing MPNs
Host and Patient Advocate Ruth Fein talked to physician-scientist Dr. Ross Levine of the Memorial Sloan Kettering Cancer Center about his research on myeloproliferative neoplasms (MPN) blood cancers.
Dr. Levine’s research focuses on the “somatic mutations in hematologic malignancies using candidate gene, genome-wide, and functional approaches” in MPN. We talked to him, in a way that everybody can understand, about what that means for patients now and for the future of MPN treatment. Also, we talked about the role of “aberrant signal transduction in malignant transformation and in the effects of mutations in epigenetic modifiers.”
This program is sponsored by Incyte and is produced in partnership with the MPNRF. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
What If I Become Resistant to Lenalidomide (Revlimid)?
One of the backbones of the myeloma treatment regimen is lenalidomide (Revlimid). But what happens when a myeloma patient becomes resistant to this widely used oral drug?
Host Cindy Chmielewski talked to myeloma expert Dr. Craig Cole of Michigan State University Breslin Cancer Center about treatment options for "life after Revlimid".
This program is sponsored by Sanofi Genzyme. This organization has no editorial control, and Patient Power is solely responsible for program content.
In Covid Times, What's a Transfusion or Phlebotomy Dependent MPN Patient To Do?
Having to account for the logistical, emotional, and medical ramifications of COVID-19 is enough to drive anyone batty. For patients who are transfusion or phlebotomy dependent, the burden is even higher.
In this week’s Answers Now: Facing MPNs our intrepid advocate-host Ruth Fein talked to Dr. John Mascarenhas, professor at Icahn School of Medicine and director of the Adult Leukemia Program at Mount Sinai, about life for transfusion or phlebotomy dependent patients.
This program is sponsored by Incyte and is produced in partnership with the MPNRF. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Latest News on CAR T-Cell Therapy for Multiple Myeloma
How can CAR T-cell therapy be used to treat multiple myeloma? Is it getting closer to being an approved treatment option? Watch as host and patient advocate Cindy Chmielewski talked to expert Dr. Sergio Giralt from Memorial Sloan Kettering Cancer Center.
What Genetic Markers Mean for Your MPN Care
Remember 2005? It’s the year three 20-somethings founded YouTube and the highest grossing movie featured a child wizard. It’s also the year that the JAK2 V617F mutation was discovered. In the intervening decade and a half, the understanding of that genetic marker, and the discovery of subsequent mutations, has radically changed our understanding of MPNs.
So, you know your markers. What does this mean for your care? Patient and journalist Ruth Fein coveredred translating genomics and prognostic models into everyday practices on this Answers Now: Facing MPNs program.
This program is sponsored by Incyte and is produced in partnership with the MPNRF. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Creating A Sustainable Support Network for MPN Patients
Having an MPN can be isolating. So can caring for someone with an MPN. Host Esther Schorr – who has been a dedicated care partner for nearly a decade – explored the role that friends and family can play in supporting an MPN patient while continuing to take care of themselves. What role can research, planning, and advocacy play in being a successful source of support? How can care partners build their own support networks so that they can remain supportive in the long term?
This program is sponsored by Bristol Myers Squibb. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Learning About Estrogen Receptor-Positive (ER+) Breast Cancer Treatments
What treatments are available for estrogen receptor-positive (ER+) breast cancer patients? Are there breast cancer clinical trials that could help? How can patients manage side effects?
Patient advocate host discussed ER+ treatments with expert Dr. Erika Hamilton from Sarah Cannon Research Institute. They were also joined by a breast cancer patient advocate to discuss their journey.
This program is supported by an educational grant from Daiichi Sankyo. This organization has no editorial control. It is produced by Patient Power and Patient Power is solely responsible for program content.
Part 1: ER+ News Ahead of San Antonio Breast Cancer Symposium
Part 2: Tips for Navigating the Doctor-Patient Relationship
Part 3: Breast Cancer Clinical Trials For ER+/Metastatic Patients
The Leading Edge of MPN Treatment
The tide of new information can be overwhelming. Hosts, Andrew Schorr & Ruth Fein, talked to Dr. Srdan Verstovsek, Professor of Medicine and a hematologist-oncologist at The University of Texas MD Anderson Cancer Center, about recent research leading to new therapies and new understandings of myeloproliferative neoplasms (MPNS) including detailed information about potential new treatments for essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF). As a number of clinical trials move through Phase Three, there are new therapies and more FDA approvals are on the horizon. There are many new treatment options to get excited about.
This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for program content.
Watching, Waiting and Decision-Making with MPNs
In the immortal words of Tom Petty, “the waiting is the hardest part.” When it comes to MPNs, making decisions around when to start a specific treatment are difficult.
In this installment of Answers Now: Facing MPNs, patient-advocate host Ruth Fein talked to Dr. Gabriela Hobbs, Clinical Director of Leukemia Service at Mass General, about the pros and cons of watch and wait. Which factors should be included in the process and how should those factors be weighted? Medical history? Symptoms? Blood numbers? Timed treatments? We also heard from a patient about her experience.
This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for program content.
Telling Others About My CLL Diagnosis
How do you tell family and friends that you have leukemia? Chronic Lymphocytic Leukemia (CLL) patients often don't "look sick" so it may be hard for your family, friends and co-workers to know what you are going through. How do you help others understand your condition?
Host and CLL patient Michele Nadeem-Baker discussed with social worker Robin Katz from Lurie Cancer Center of Northwestern University communication tips for people living with CLL, and the best way to share details of their condition.
This is a sponsored program where organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Part 1: Telling Others About My CLL Diagnosis
Part 2: Should I Share My CLL Diagnosis While In Watch and Wait?
PV, ET and MF: Experts Explain What to Worry About
Rare blood cancers are tricky for doctors to recognize. So how does a patient begin to wrap their head around such a disease?
In this installment of Facing MPNs Answers Now, Host Ruth Fein, who has had all three types of MPN over the course of 25 years, dove into the three types of myeloproliferative neoplasms: essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). We addressed common questions MPN patients have when they're newly diagnosed and the questions doctors wish people would ask to set themselves up for successful management and self-advocacy over the long term. Watch as our host discussed these issues with Dr. Michael J. Mauro of Memorial Sloan Kettering Cancer Center and Dr. Abdulraheem Yacoub of The University of Kansas Cancer Center.
This program is sponsored by Bristol Myers Squibb. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Cancer In The Workplace: Do I Have To Tell My Boss?
The recent death of Black Panther star Chadwick Boseman from colon cancer shocked the world, including his co-stars and directors. Boseman chose not to disclose his 4 year cancer battle, which included surgeries and chemotherapy. Had his cancer diagnosis and treatments been public, would that have changed his career path? For most of us, whether to share a cancer diagnosis and treatment to our employers is a big decision. What are our legal rights? What happens to our work if we disclose our cancer? What if we choose to keep our health information private?
Dr. Mark Lewis, a practicing Utah oncologist living with cancer, Jill Silverstein, employment and civil rights attorney and Esther Schorr, host and patient advocate, answered questions about cancer and the workplace.
Part 1: Diagnosing My Own Cancer: Oncologist Shares His Cancer Story
Part 2: Cancer in the Workplace: Do I Need To Tell My Boss?
Part 3: Cancer in the Workplace: What Are Reasonable Accommodations?
When Is A Stem Cell Transplant Necessary to Treat Myeloma?
Is a stem cell transplant right for me? How and when does a stem cell transplant fit into treating myeloma? With all the new advances in myeloma treatments, are stem cell transplants still performed as often?
Host and 3-time stem cell transplant survivor, Jack Aiello sat down with multiple myeloma expert, Dr. Amrita Krishnan from City of Hope to discuss these questions.
Part 1: Autologous Stem Cell Transplant for Multiple Myeloma
Part 2: Is Stem Cell Transplant Best for Relapsed Myeloma Patients?
Part 3: Stem Cell Transplant Expert Talks Recovery & COVID Vaccine
Managing MPN Anxiety During COVID-19
Having a myeloproliferative neoplasm like essential thrombocythemia (ET), polycythemia vera (PV) or myelofibrosis (MF) is anxiety producing enough, now add the stress of COVID-19, and many people find their anxiety is through the roof. Are there ways people can cope with the added stress and find ways to calm down all while still getting the treatment you need?
Host and MPN patient Andrew Schorr discussed these issues with counseling psychologist, Dr. Jim Healy. He knows the MPN perspective all too well because his wife, Madonna has been living with polycythemia vera (PV) for over 10 years.
This program is sponsored by Bristol Myers Squibb. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
What's My Risk for MPN Disease Progression?
Triple Negative Breast Cancer Treatment News
What treatments are available for triple negative breast cancer patients? Are there triple negative breast cancer clinical trials that could help? How can patients manage triple negative breast cancer chemo side effects?
Patient advocate host Ricki Fairley discussed triple negative breast cancer treatments with expert Dr. Sara Tolaney from Dana-Farber Cancer Institute about these important treatment questions. Send your questions for the expert in advance to breast@patientpower.info.
This program is supported by an educational grant from Daiichi Sankyo. This organization has no editorial control. It is produced by Patient Power and Patient Power is solely responsible for program content.
Part 1: Treatments for Early-Stage Triple-Negative Breast Cancer (TNBC)
Part 2: Triple-Negative Breast Cancer Treatment Options By Subtype
Part 3: Managing the Side Effects of Triple-Negative Breast Cancer
Aggressive CLL Treatment Options: Are They Right for Me?
Part 1: When Would My CLL Need Aggressive Treatment?
Part 2: Aggressive Treatment Options: When Are They Right for CLL Patients?
KRAS Lung Cancer Treatment News
What's the latest treatment news for lung cancer patients with the KRAS (Kirsten rat sarcoma viral oncogene homologue) mutation?
Terri Conneran, host and founder of the KRAS Kickers Support Group, WAS joined by lung cancer experts, Dr. Jyoti Patel from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Dr. Jessica Lin from Harvard Medical School.
Managing Side Effects of MPN Treatment
Myeloproliferative neoplasms (MPNs) can have symptoms that reduce quality of life and it’s not uncommon for treatments to have bothersome or even serious side effects that may reduce quality of life. How can you and your doctor work together to manage these?
Host Andrew Schorr talked to MPN experts from The University of Texas MD Anderson Cancer Center, Dr. Naveen Pemmaraju and Physician Assistants Rodney Haltom and Julie Huynh-Lu on the various side effects of MPN treatments and how to get relief. They covered side effects including itching, fatigue, and many more.
This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power and Patient Power is solely responsible for the content.
Part 1: Is There Help for Fatigue and Insomnia from MPN Treatment?
Part 2: MPN Treatment: Managing Itching, Sweating and Bone Pain
CLL Expert: Ask Me Anything!
Do you have chronic lymphocytic leukemia questions to ask? During this CLL Ask The Expert Program, host Andrew Schorr spoke with CLL expert Dr. Richard Furman from Weill Cornell Medicine to answer the latest CLL questions related to treatment and news.
This program is sponsored by AbbVie, Inc., Genentech, Inc. and Adaptive Biotechnologies. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Part 1: Latest News on BTK Inhibitors for CLL
Part 2: Monitoring CLL: Determining Treatment Plan and MRD Testing
Part 3: Latest CLL Research on Scans, Treatments and 17p Deletion
Exercising Safely During COVID-19
Esther Schorr joined avid runner Kenny Capps, who is living with multiple myeloma, and cancer exercise specialist Cathy Skinner from Thrivors, Inc. They discussed how cancer patients can stay active while in quarantine, online resources and creative at-home objects that can be used for exercise.
New Treatments For Essential Thrombocythemia
Part 1: Essential Thrombocythemia and COVID-19 Complication Risk
Part 2: What Essential Thrombocythemia Treatments Are Available?
Part 3: Current Research on Essential Thrombocythemia
Part 4: Can Diet and Exercise Help Essential Thrombocythemia?
Managing Side Effects of New Myeloma Drugs
Multiple Myeloma patients have more treatment options than ever before but how are side effects and toxicities managed?
Host and patient advocate Cindy Chmielewski talked to Dr. Cesar Rodriguez from Wake Forest Baptist Health and Dr. Natalie S. Callander from the University of Wisconsin School of Medicine and Public Health about new myeloma drugs like belamaf, ide-cel, CAR-T, and selinexor. They also discussed how experts are managing toxicities from these new treatment options.
Part 1: Managing the Side Effects of Blenrep for Myeloma
Part 2: Side Effects of Myeloma Treatment: What is Too Much?
Part 3: Darzalex Faspro: What is it and Does it Have Side Effects?
Part 4: What is Selinexor (Xpovio) and Are There Side Effects?
Part 5: Isatuximab-irfc (Sarclisa) As a Multiple Myeloma Treatment
Breast Cancer Care During COVID-19
Part 1: Is Breast Cancer Treatment Safe During COVID-19?
Part 2: Telemedicine for At-Risk Women with Breast Cancer
Part 3: COVID-19 Positive with Breast Cancer
Part 4: Accessing Breast Cancer Treatment During Coronavirus
Part 5: What’s the Risk of COVID-19 for Breast Cancer Patients?
CLL Patients and COVID-19: What's My Risk?
Part 1: New Study Shows COVID-19 Severity in CLL Patients
Part 2: Should I Get a COVID-19 Vaccine if I have CLL?
Part 3: CLL and COVID-19: Do I Need to Stay Quarantined?
Part 4: COVID-19 Treatments in the News: What’s True?
Part 5: What's My Risk of COVID-19 Reinfection if I Have Antibodies?
Epidermal Growth Factor Receptor (EGFR) Lung Cancer News
Part 1: EGFR Lung Cancer Treatment News
Part 2: What is the First Line Treatment for EGFR-Mutant NSCLC?
Latest News For Treating Pediatric Acute Lymphoblastic Leukemia
Part 1: Treatments for Childhood Acute Lymphoblastic Leukemia
Part 2: Immunotherapy and Chemotherapy for Pediatric ALL
Part 3: Childhood Acute Leukemia: Advice For Parents
Would I Be a Good Candidate for an MPN Clinical Trial?
Part 1: Would I Be A Good Candidate For An MPN Clinical Trial?
CLL Survivors Share their CAR-T Cell Experiences
Andrew Schorr talked to expert Dr. Nitin Jain from the University of Texas MD Anderson Cancer Center. They were joined by patient advocates, David Garcia and Larry Saltzman who shared their own CAR-T cell experiences. The panel also discussed if you can get CAR-T cell therapy during the COVID-19 pandemic.
Polycythemia Vera and Clotting: Does COVID-19 Make Me High Risk?
Expert Advice on Managing Side Effects of Cancer Treatment
Cancer, along with the side effects from treatments, is a formidable foe. Palliative care is a means of managing fatigue, pain, nausea, sleeplessness and more.
Often confused with hospice care, palliative care is finally receiving the attention it deserves. From mitigating side effects to improving overall quality of life, it has become an integral part of cancer care. Dr. Subbiah Ishwaria, a leading expert from the University of Texas MD Anderson Cancer Center, and patient advocate Stacey Tinianov, discussed the benefits of palliative care and explain how to incorporate it into your treatment plan.
Managing the Costs of CLL Treatment
CLL treatment can be expensive, particularly over time and when it's treated like a chronic condition. Is there a benefit to fixed duration therapy? Does it keep costs down? Are there financial resources available to help?
Host Andrew Schorr talked to CLL expert Dr. Thomas Kipps of UC San Diego Moores Cancer Center and Dr. Jennifer A. Woyach of The Ohio State University about where cost concerns come into play when making treatment decisions. They were joined by a patient advocate.
This program is sponsored by AbbVie, Inc. and Genentech, Inc. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content
A Cancer Patient's Guide To Masks
Will COVID-19 Influence CLL Care Long Term?
The recent coronavirus pandemic temporarily disrupted plans for many, but will it shift the thinking of chronic lymphocytic leukemia (CLL) treatment forever? Host and 20+ year CLL patient Andrew Schorr talked to leading expert Dr. Nitin Jain from The University of Texas MD Anderson Cancer Center and Dr. Alexey Danilov from City of Hope along with another long-term CLL survivor.
Although this is a sponsored program, Patient Power maintains editorial control and is solely responsible for the content of this program.
Part 1: Has the Pandemic Changed CLL Treatment Approaches?
Part 2: What CLL Patients on Watch and Wait Need to Know Right Now
Part 3: Clinical Trials Explore Use of BTK Inhibitors in COVID-19
The Future of MPN Research After COVID-19
With the coronavirus pandemic, has research on myeloproliferative neoplasms (MPNs) halted? Are clinical trials still moving forward? For our latest Answers Now program, host and MPN patient Andrew Schorr talked to two MPN researchers, Dr. Naveen Pemmaraju of the University of Texas MD Anderson Cancer Center and Dr. Jeanne Palmer of the Mayo Clinic Arizona.
This program is sponsored by Sierra Oncology. This organization has no editorial control. It is produced by Patient Power in partnership with the MPN Research Foundation. Patient Power is solely responsible for the program content.
An Honest Conversation About Masks and COVID-19
What should you say to others about why you're wearing a mask during this coronavirus pandemic?
Breast cancer survivor Greta Beekhuis was hassled in a store parking lot when she wore a mask to pick up her medicine. Greta shared her story and what she wishes she would have said that day. Lung cancer patient Gina Hollenbeck wore a mask to the gym and then posted a photo of herself on social media, along with her reasoning behind it. She shared her experience about backlash she received.
Social work program manager Harold Dean from UAMS Myeloma Center provided guidance for how, or if, to have those difficult conversations with family, friends, neighbors and people you encounter.
Part 1: Breast Cancer Patient Hassled For Wearing
Mask
Latest Myeloma Treatment News From ASCO
Where can you put 50 years of myeloma patient wisdom to work for you so you or a loved one gets the best care? Where? On Patient Power’s Myeloma Answers Now program, FOUR very experienced patients/support leaders gave their perspectives on myeloma news from ASCO, the world’s largest cancer medical meeting. They explained and took questions on what you should talk to your doctor about.
Part 1: What Does the ENDURANCE Trial Mean for Myeloma Patients?
Part 2: CAR T-Cell Clinical Trial Updates for Myeloma Patients
Part 3: What Does the StaMINA Trial Mean for Myeloma Patients?
Is Financial Help Available If I Lost Income Due to COVID-19?
Navigating the costs of cancer care can be daunting enough but what if you have a change in income due to the coronavirus pandemic? That change in income can impact programs you might be enrolled in like Medicaid and Medicare along with co-pay assistance programs. Andrew Schorr led our Answers Now program as he talked to two leading financial navigators, Dan Sherman and Aimee Hoch, on how to deal with these changes and resources that can help.
This is a sponsored program where organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Part 1: How Can I Find a Financial
Navigator
Part 2: Is Financial Help Available for Cancer Patients?
Should I Delay CLL Treatment Because of the Coronavirus Pandemic?
Should you delay CLL treatment because of the coronavirus? Whether this is your first treatment or if you need re-treatment after coming out of remission, this is an important question to get answered! What are the pros and cons of initiating or delaying treatment?
Host and CLL patient advocate Andrew Schorr got the answers from CLL experts Dr. Philip Thompson from the University of Texas MD Anderson Cancer Center and Dr. John Allan from Weill Cornell Medicine. CLL patient advocate Jeff Folloder also joined to share his patient perspective.
This program is sponsored by AbbVie, Inc. and Genentech, Inc. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
Part 1: CLL Retreatment Amidst Coronavirus
Part 2: Is CLL Care Finally Returning to Normal?
COVID-19 Testing for MPN Patients
Myeloproliferative neoplasm patients want to know if they can get tested for COVID-19, if they can trust the test results and if their MPN affects the results. Host and MPN patient Andrew Schorr got the facts from MPN experts, Dr. Brady Stein from Lurie Cancer Center in Chicago and Dr. Ellen Ritchie from Weill Cornell in NYC. They were joined by MPN patient advocate and Dr. Ritchie's patient, Ruth Fein who shared her experience with COVID-19 symptoms.
This program is sponsored by Incyte. This organization has no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.
The Latest in Blood and Antibody Tests for COVID-19
We are learning more about antibody tests for COVID-19. Host Andrew Schorr led our follow-up session with noted laboratory science experts Susan Leclair, PhD, and Jim Griffith, PhD.
What's My Current Risk for Coronavirus?
What's the latest data on my risk of getting the coronavirus and the complications that could come from it as a CLL patient? Host Andrew Schorr spoke live with Dr. Matthew Davids from Dana-Farber Cancer Institute about his experience treating patients in Boston. They were joined by CLL patient advocate Michele Nadeem-Baker who shared her patient perspective.
Although this is a sponsored program, Patient Power maintains editorial control and is solely responsible for the content of this program.
Part 1: What’s My Current Risk for
Coronavirus?
Part 2: Does Living With CLL Increase My Risk for Coronavirus?
Cancer and COVID-19, When Will I Be Safe?
Throughout the country, states are “opening up” amidst the coronavirus pandemic. What do cancer patients and other immunocompromised individuals need to know? Andrew Schorr talked to two experts from Sarah Cannon Research Institute at Tennessee Oncology.
Making Sense of New Myeloma Treatments During Coronavirus
Amidst the coronavirus pandemic, new myeloma medicines are still being approved. How do patients and their doctors incorporate these new therapies during this time of telemedicine and adjusted treatment schedules? Dr. Saad Usmani from Levine Cancer Institute and leading patient advocate Jack Aiello joined us to discuss.
This program is sponsored by Sanofi Genzyme. This organization has no editorial control. Patient Power is solely responsible for program content.
What Do MPN Patients Need to Know About COVID-19?
We continue to learn what COVID-19 means for MPN patients from top experts. Two experts from leading centers, Dr. Raajit Rampal from Memorial Sloan Kettering in New York City, and Dr. Srdan Verstovsek from MD Anderson in Houston, answered audience questions and explained the latest research. Michelle Woehrle, from the MPN Research Foundation also joined with an update on resources that can help.
Spirituality, Mindfulness and Gratitude
Two spiritual leaders - Rabbi Jill Zimmerman and Pastor Rodrick Echols - joined us to discuss how to tap into your individual version of spirituality, mindfulness and gratitude as we all face this trying time of the coronavirus pandemic.